Clinical Trials

Pilot Trial of pTVG-HP (MVI-816) DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer




Protocol Principal Investigator

Douglas McNeel, MD, PhD


University of Wisconsin Carbone Cancer Center


This randomized pilot trial studies vaccine therapy and pembrolizumab in treating patients with prostate cancer that does not respond to treatment with hormones (hormone-resistant) and has spread to other places in the body (metastatic). Vaccines made from deoxyribonucleic acid (DNA), such as pTVG-HP plasmid DNA vaccine, may help the body build an effective immune response to kill tumor cells. Monoclonal antibodies, such as pembrolizumab, may find tumor cells and help kill them. Giving pTVG-HP plasmid DNA vaccine and pembrolizumab may kill more tumor cells.

Start Date

July 1, 2015

Estimated Primary Completion Date

July 30, 2021

Estimated  Completion Date

July 30, 2021


Madison Vaccines, Inc (MVI)
Prostate Cancer Foundation
University of Wisconsin-Madison

Interested in participating? Contact the UW Carbone Cancer Center